Point Biopharma Global

POINT Biopharma Global, Inc. is a precision oncology company, which engages in the development and commercialization of radiopharmaceuticals for the treatment of cancer. It offers CanSEEK, a technology which aims to minimize radiopharmaceutical toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety. The company was founded by Joe McCann and Neil E. Fleshner on April 15, 2020 and is headquartered in Indianapolis, IN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.

Eli Lilly

INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," said Jacob Van Naarden, executive vice president and president, Loxo@Lilly.

Lilly Completes Acquisition of POINT Biopharma

Bristol-Myers

Fusion Pharmaceuticals

RayzeBio Inc

Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday.

Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target

Lantheus Holdings

Shares of Lantheus Holdings Inc. LNTH, -2.38% and Point Biopharma Global Inc. PNT, +2.26% fell sharply premarket on Monday after the companies released new data from a trial of their experimental treatment for prostate cancer. The therapy, Lu-PNT2002, met the trial's primary goal, with a median progression-free survival of 9.5 months, compared with six months for patients on an alternative treatment, an androgen receptor pathway inhibitor, the companies said in a release.

Lantheus and Point Biopharma shares drop on prostate cancer treatment data

Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS)

Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

INDIANAPOLIS , Dec. 18, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m.

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023

POINT Biopharma Global Inc. (PNT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

POINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should Know

Eli Lilly , on Monday, gave Point Biopharma Global shareholders more time to sell their stock to the drugmaker amid low participation since the offer price was below the current stock price of the radiopharma developer.

Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15

INDIANAPOLIS , Dec. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m.

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023

Eli Lilly on Friday extended the deadline for Point Biopharma Global shareholders by about two weeks to Dec. 1 to sell their stock, due to low participation.

Eli Lilly extends tender offer to buy Point Biopharma after low participation

INDIANAPOLIS , Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m.

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023

INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC") has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ: PNT) radioactive materials license (the "NRC Consent"), which will occur following the completion of Lilly's previously announced tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT, for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. Obtaining the NRC Consent is the last regulatory approval necessary for the consummation of the transaction.

Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma

Announced a definitive agreement to be acquired by Lilly for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion); transaction expected to close near the end of 2023 Announced a definitive agreement to be acquired by Lilly for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion); transaction expected to close near the end of 2023

POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

INDIANAPOLIS , Nov. 8, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at one minute past 11:59 p.m.

Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma

Mirati Therapeutics

Pfizer

The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.

Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of POINT Biopharma Global, Inc. (NasdaqCM: PNT) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of POINT will receive $12.50 in cash for each share of POINT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq.

POINT BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of POINT Biopharma Global, Inc. - PNT

On Tuesday, Eli Lilly agreed to acquire Point Biopharma for $12.50 per share in cash -- an 87% premium from Monday's close. The deal isn't subject to financing conditions, but still requires a license transfer approval from the U.S. Nuclear Regulatory Commission as well as the successful tender of a majority of Point's common shares outstanding by Lilly.

Why Point BioPharma Global Stock Skyrocketed 86% This Week

Point Biopharma focuses on oncology therapies. The company's lead therapy is PNT2002 to treat prostate cancer.

Why Shares of Point Biopharma Global Are Soaring Tuesday

Shares of POINT Biopharma Global (PNT) skyrocketed over 80% in early trading on Tuesday after Eli Lilly (LLY) agreed to buy the radiopharmaceutical firm for $1.4 billion to expand its cancer-fighting treatments.

Eli Lilly Buys POINT Biopharma to Boost Its Cancer-Fighting Therapies

MILWAUKEE , Oct. 3, 2023 /PRNewswire/ -- Ademi LLP is investigating POINT (Nasdaq: PNT) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly. Click here to learn how to join the action https://www.ademilaw.com/case/point-biopharma-global-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether POINT Biopharma Global, Inc. has obtained a Fair Price in its transaction with Eli Lilly

Shares of Point Biopharma Global Inc (NASDAQ: PNT) close to doubled this morning after Eli Lilly & Co (NYSE: LLY) announced plans of acquiring the cancer treatment company. Details of Lilly-Point agreement Lilly is willing to pay about $1.4 billion for Point Biopharma that values each of its share at $12.

Point Biopharma stock nearly doubles on Eli Lilly deal

Eli Lilly said Tuesday it will buy cancer specialist Point Biopharma Global for $1.4 billion, launching PNT stock to a two-year high.

Point Biopharma Stock Launches 84% On Eli Lilly's $1.4 Billion Takeover

Shares in Point Biopharma Global jumped 84% following the announcement that pharmaceutical giant Eli Lilly and Co (NYSE:LLY) will acquire the company for $1.4 billion (£1.03 billion). The acquisition allows Lilly to expand its portfolio of experimental cancer therapies, particularly in the area of radioligand treatments.

Point Biopharma shares storm ahead 84% after Eli Lily's $1.4bn bid

Point Biopharma (NASDAQ: PNT ) stock is rocketing higher on Tuesday after the radiopharmaceutical company announced an acquisition deal. Eli Lilly (NYSE: LLY ) has agreed to acquire Point Biopharma in a $1.4 billion deal.

Why Is Point Biopharma (PNT) Stock Up 84% Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of POINT Biopharma Global, Inc. (NASDAQ: PNT) to Eli Lilly for $12.50 per share in cash is fair to POINT Biopharma shareholders. Halper Sadeh encourages POINT Biopharma shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whet.

PNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of POINT Biopharma Global, Inc. Is Fair to Shareholders

Eli Lilly will acquire radiopharmaceutical company Point Biopharma Global for $12.50 a share.

News for Point Biopharma Global Stock (PNT)